mbiomics GmbH is a biotechnology research startup based in Munich, Germany, dedicated to improving people's lives by better understanding the microbiome. With a recent Series A funding round of $13,945,000 from MIG Capital, Bayern Kapital GmbH, and HTGF | High-Tech Gründerfonds, mbiomics is well-positioned to advance its cutting-edge research and develop novel therapeutics.

The microbiome is a complex and diverse ecosystem of microorganisms that live within and on our bodies, playing crucial roles in our health and well-being. However, our understanding of the microbiome is still limited despite its importance. This is where mbiomics comes in: their innovative approach aims to fully understand the secrets of the microbiome, identifying the microorganisms present and how they interact with each other and the human host.

By better understanding, the microbiome, mbiomics hopes to develop targeted therapies that can improve the lives of people suffering from a range of conditions, from gastrointestinal disorders to skin conditions and beyond.

At the same time, their research may also shed new light on how to lead a healthy life, providing insights into how our microbiome is influenced by diet, lifestyle, and environmental factors. Visit our Latest funding round for more information: https://founderlodge.com/round/mbiomics-GmbH-raises-13945000-Series-A-2023-03-24-Laura-Figulla-MTE0MjU